AbbVie Tumbles After New Schizophrenia Drug Fails in Two Trials
3 days ago · AbbVie Inc. shares sank in early trading after two mid-stage trials of its drug to treat schizophrenia failed to meet their primary goal, a blow to the company’s $8.7 billion acquisition of ...
Despite setback, AbbVie’s big bet on neuroscience has yet to
2 days ago · Nov. 12, 2024. National Biotech Reporter. For AbbVie, the good news this week is that the failure of a high-profile schizophrenia drug in two key trials hardly marks its last opportunity to make ...
AbbVie Provides Update on Phase 2 Results for Emraclidine in …
3 days ago · News provided by AbbVie Nov 11, 2024, 08:30 ET. Share this article. Share to X. Share this article. Share to X. EMPOWER-1 and EMPOWER-2 Phase 2 clinical trials did not meet their primary endpoint ...
Schizophrenia drug AbbVie picked up in $9 billion acquisition
3 days ago · Nov. 11, 2024. National Biotech Reporter. AbbVie said Monday that its experimental treatment for schizophrenia failed to significantly help patients in two trials, a blow to the company, which got ...
AbbVie News Center - News
3 days ago · AbbVie News Center - News. Latest news. November 11, 2024. AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia. November 07, 2024. Allergan Aesthetics Celebrates Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day. October 31, 2024.
AbbVie's closely watched schizophrenia drug fails two studies, …
3 days ago · AbbVie shares fell over 12% on Monday after an experimental schizophrenia drug the company acquired last year failed two mid-stage studies, widening rival Bristol Myers Squibb's lead in the market ...
AbbVie raises 2024 profit forecast on strong sales of key drugs …
Oct 30, 2024 · AbbVie raised its annual profit forecast after strong sales of its newer immunology drugs and key cancer treatment helped the company beat Wall Street estimates for third-quarter earnings,...
AbbVie Stock Slides on Schizophrenia Drug Study Failure
3 days ago · AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. ... Stock Market News, Nov. 11, 2024: Dow Ends Higher ...
AbbVie shares tumble after schizophrenia drug disappoints
3 days ago · The Chicago-based drugmaker said on Monday its novel schizophrenia drug Emraclidine failed to show “a statistically significant reduction” in psychotic symptoms after six weeks, compared with ...
AbbVie to Acquire Landos Biopharma, Further Strengthening its ... - News
Mar 25, 2024 · AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases. Landos' lead asset, NX-13, is a first-in-class, oral NLRX1 agonist in Phase 2 for the treatment of ulcerative colitis (UC) NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 / PRNewswire / -- AbbVie Inc. (NYSE: ABBV) ("AbbVie") and ...
- Some results have been removed